Conditional Recurrence-Free Survival after Oncologic Extended Resection for Gallbladder Cancer: An International Multicenter Analysis.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
16
04
2020
accepted:
05
12
2020
pubmed:
6
3
2021
medline:
15
5
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
Data to guide surveillance following oncologic extended resection (OER) for gallbladder cancer (GBC) are lacking. Conditional recurrence-free survival (C-RFS) can inform surveillance. We aimed to estimate C-RFS and identify factors affecting conditional RFS after OER for GBC. Patients with ≥ T1b GBC who underwent curative-intent surgery in 2000-2018 at four countries were identified. Risk factors for recurrence and RFS were evaluated at initial resection in all patients and at 12 and 24 months after resection in patients remaining recurrence-free. Of the 1071 patients who underwent OER, 484 met the inclusion criteria; 290 (60%) were recurrence-free at 12 months, and 199 (41%) were recurrence-free at 24 months. Median follow-up was 24.5 months for all patients and 47.21 months in survivors at analysis. Five-year RFS rates were 47% for the overall population, 71% for patients recurrence-free at 12 months, and 87% for the patients without recurrence at 24 months. In the entire cohort, the risk of recurrence peaked at 8 months. T3-T4 disease was independently associated with recurrence in all groups: entire cohort [hazard ratio (HR) 2.16, 95% confidence interval (CI) 1.49-3.13, P < 0.001], 12-month recurrence-free (HR 3.42, 95% CI 1.88-6.23, P < 0.001), and 24-month recurrence-free (HR 2.71, 95% CI 1.11-6.62, P = 0.029). Of the 125 patients without these risk factors, only 2 had recurrence after 36 months. C-RFS improves over time, and only T3-T4 disease remains a risk factor for recurrence at 24 months after OER for GBC. For all recurrence-free survivors after 36 months, the probability of recurrence is similar regardless of T category or disease stage.
Sections du résumé
BACKGROUND
BACKGROUND
Data to guide surveillance following oncologic extended resection (OER) for gallbladder cancer (GBC) are lacking. Conditional recurrence-free survival (C-RFS) can inform surveillance. We aimed to estimate C-RFS and identify factors affecting conditional RFS after OER for GBC.
PATIENTS AND METHODS
METHODS
Patients with ≥ T1b GBC who underwent curative-intent surgery in 2000-2018 at four countries were identified. Risk factors for recurrence and RFS were evaluated at initial resection in all patients and at 12 and 24 months after resection in patients remaining recurrence-free.
RESULTS
RESULTS
Of the 1071 patients who underwent OER, 484 met the inclusion criteria; 290 (60%) were recurrence-free at 12 months, and 199 (41%) were recurrence-free at 24 months. Median follow-up was 24.5 months for all patients and 47.21 months in survivors at analysis. Five-year RFS rates were 47% for the overall population, 71% for patients recurrence-free at 12 months, and 87% for the patients without recurrence at 24 months. In the entire cohort, the risk of recurrence peaked at 8 months. T3-T4 disease was independently associated with recurrence in all groups: entire cohort [hazard ratio (HR) 2.16, 95% confidence interval (CI) 1.49-3.13, P < 0.001], 12-month recurrence-free (HR 3.42, 95% CI 1.88-6.23, P < 0.001), and 24-month recurrence-free (HR 2.71, 95% CI 1.11-6.62, P = 0.029). Of the 125 patients without these risk factors, only 2 had recurrence after 36 months.
CONCLUSION
CONCLUSIONS
C-RFS improves over time, and only T3-T4 disease remains a risk factor for recurrence at 24 months after OER for GBC. For all recurrence-free survivors after 36 months, the probability of recurrence is similar regardless of T category or disease stage.
Identifiants
pubmed: 33666814
doi: 10.1245/s10434-021-09626-3
pii: 10.1245/s10434-021-09626-3
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2675-2682Subventions
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States
Références
Vinuela E, Vega EA, Yamashita S, et al. Incidental gallbladder cancer: residual cancer discovered at oncologic extended resection determines outcome: a report from high- and low-incidence countries. Ann Surg Oncol. 2017;24(8):2334–43.
doi: 10.1245/s10434-017-5859-6
Margonis GA, Gani F, Buettner S, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB. 2016;18(11):872–8.
doi: 10.1016/j.hpb.2016.05.016
Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.
doi: 10.1002/cncr.11699
Kawaguchi Y, Lillemoe HA, Panettieri E, et al. Conditional recurrence-free survival after resection of colorectal liver metastases: persistent deleterious association with RAS and TP53 co-mutation. J Am Coll Surg. 2019;229(3):286-294.e281.
doi: 10.1016/j.jamcollsurg.2019.04.027
Kawaguchi Y, Lillemoe HA, Vauthey JN. Comment on “Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma.” Ann Surg. 2020;271(2):e17.
doi: 10.1097/SLA.0000000000003610
Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol . 1994;10(1):2–6.
doi: 10.1002/ssu.2980100103
Kim YJ, Kim K. Conditional survival in patients with gallbladder cancer. Chin J Cancer. 2017;36(1):85.
doi: 10.1186/s40880-017-0252-1
Buettner S, Margonis GA, Kim Y, et al. Changing odds of survival over time among patients undergoing surgical resection of gallbladder carcinoma. Ann Surg Oncol. 2016;23(13):4401–9.
doi: 10.1245/s10434-016-5470-2
Vega EA, Vinuela E, Okuno M, et al. Incidental versus non-incidental gallbladder cancer: index cholecystectomy before oncologic re-resection negatively impacts survival in T2b tumors. HPB. Jan 30 2019.
Vega EA, Vinuela E, Sanhueza M, et al. Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator. Eur J Surg Oncol. 2019.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2017;17(6):1471-1474.
Sakata J, Shirai Y, Wakai T, Ajioka Y, Hatakeyama K. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol. 2010;17(7):1831–40.
doi: 10.1245/s10434-009-0899-1
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
Gasser TaM HG. Smoothing Techniques for Curve Estimation. Berlin: Springer; 1979.
doi: 10.1007/BFb0098486
Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363–71.
doi: 10.1161/CIRCOUTCOMES.110.957951
Lebel S, Ozakinci G, Humphris G, et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016;24(8):3265–8.
doi: 10.1007/s00520-016-3272-5
Printz C. More research needed to help survivors with fear of recurrence. Cancer. 2019;125(5):665.
doi: 10.1002/cncr.32014
National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 1.2019). 2018; https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf . Accessed February 15, 2019.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
doi: 10.1056/NEJMoa0908721
Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.
doi: 10.1002/cncr.10831
Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.
doi: 10.1200/JCO.2014.60.2219
Edeline J, Bonnetain F, Phelip JM, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol. 2017;35(4_suppl):225–225.
doi: 10.1200/JCO.2017.35.4_suppl.225
Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 2017;35(15_suppl):4006–4006.
doi: 10.1200/JCO.2017.35.15_suppl.4006
Javle M, Rashid A, Churi C, et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014;45(4):701–8.
doi: 10.1016/j.humpath.2013.11.001
Bang YJ, Doi T, Braud FD, et al. 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028. Eur J Cancer. 2012;51:S112.
doi: 10.1016/S0959-8049(16)30326-4
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
doi: 10.1126/science.aaa8172
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.
doi: 10.1016/S0065-2776(06)90001-7
Nakakubo Y, Miyamoto M, Cho Y, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer. 2003;89(9):1736–42.
doi: 10.1038/sj.bjc.6601331
Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109(10):2665–74.
doi: 10.1038/bjc.2013.610
Takagi S, Miyagawa S, Ichikawa E, et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol. 2004;35(7):881–6.
doi: 10.1016/j.humpath.2004.03.016
Oshikiri T, Miyamoto M, Shichinohe T, et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol. 2003;84(4):224–8.
doi: 10.1002/jso.10321
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–5.
doi: 10.1126/science.1251102
Holcombe RF, Xiu J, Pishvaian MJ, et al. Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets. J Clin Oncol. 2015;33(3):285–285.
doi: 10.1200/jco.2015.33.3_suppl.285